Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook

By Reuters News

** Shares of Australia's Neuren Pharmaceuticals NEU.AX climb as much as 17.7% to A$23.3, marking their biggest intraday pct gain since June 29

** Shares hit their highest level since August 20

** Biopharmaceutical co upgrades 2026 income forecast from trofinetide (DAYBUE) to $91 million-$93 million from $53 million-$56 million. Trofinetide is used for the treatment of Rett Syndrome, a genetic neurological and developmental disorder

** Co says partner Acadia Pharmaceuticals raised full-year global sales forecast for DAYBUE to $505 million-$520 million from $480 million-$510 million

** Adds Q3 DAYBUE net sales rose 39% year-on-year to $140 million

** Adds Japan results of Phase 3 trial of DAYBUE support a planned regulatory filing in 2027 and potential launch in 2028

** More than 790,000 shares change hands, about 2.3x the 30-day average

** YTD, stock up 23.6%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.